[Multiple myeloma: the role of angiogenesis and therapeutic application of thalidomide].
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D002352:Carrier Proteins / Q000378:metabolism; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins; D015850:Interleukin-6 / Q000378:metabolism; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D019947:Receptors, Interleukin-6 / Q000378:metabolism; D013792:Thalidomide / Q000627:therapeutic use*; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
D020533:Angiogenesis Inhibitors; D002352:Carrier Proteins; D036341:Intercellular Signaling Peptides and Proteins; D015850:Interleukin-6; D019947:Receptors, Interleukin-6; D042461:Vascular Endothelial Growth Factor A; C070699:FGFBP1 protein, human; D013792:Thalidomide
Szpiczak mnogi--rola angiogenezy i zastosowanie talidomidu.